Merck (MRK) Non-Current Assets (2009 - 2026)
Merck (MRK) posted quarterly Non-Current Assets of $125.0 million for Q1 2026, down 99.84% year-over-year from $79.6 billion in Q1 2025, and little changed quarter-over-quarter from $125.0 million in Q4 2025.
Merck (MRK) Non-Current Assets (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Non-Current Assets for 18 consecutive years, with $125.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 99.84% year-over-year to $125.0 million; the TTM figure through Mar 2026 stood at $125.0 million (down 99.96% YoY), while the FY2025 annual figure was $125.0 million, changed N/A from the prior year.
- Non-Current Assets held at $125.0 million in Q1 2026 per MRK's latest filing, from $125.0 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $82.0 billion in Q3 2025 and bottomed at $125.0 million in Q4 2025.
- Historically, Non-Current Assets has averaged $66.5 billion across 5 years, with a median of $74.5 billion in 2023.
- Annual changes were most pronounced in 2022 — Non-Current Assets climbed 20.89% — and 2026, when it tumbled 99.84%.
- Merck's Non-Current Assets stood at $73.4 billion in 2022, then increased by 1.46% to $74.5 billion in 2023, then rose by 3.58% to $77.2 billion in 2024, then slumped by 99.84% to $125.0 million in 2025, then changed by 0.0% to $125.0 million in 2026.
- Business Quant data shows MRK's Non-Current Assets at $125.0 million in Q1 2026, $125.0 million in Q4 2025, and $82.0 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 141.29 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 101.45 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 125.00 Mn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 94.68 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 87.87 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 60.68 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 35.42 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 159.77 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 59.27 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 113.37 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 125.00 Mn |
| Mar 31, 2026 | 125.00 Mn |
| Dec 31, 2025 | 125.00 Mn |
| Sep 30, 2025 | 81.99 Bn |
| Jun 30, 2025 | 80.46 Bn |
| Mar 31, 2025 | 79.62 Bn |
| Sep 30, 2024 | 77.17 Bn |
| Jun 30, 2024 | 74.43 Bn |
| Mar 31, 2024 | 74.40 Bn |
| Dec 31, 2023 | 74.51 Bn |
| Sep 30, 2023 | 74.77 Bn |
| Jun 30, 2023 | 74.49 Bn |
| Mar 31, 2023 | 74.39 Bn |
| Dec 31, 2022 | 73.44 Bn |
| Sep 30, 2022 | 73.52 Bn |
| Jun 30, 2022 | 74.98 Bn |
| Mar 31, 2022 | 75.48 Bn |
| Dec 31, 2021 | 75.43 Bn |
| Sep 30, 2021 | 62.44 Bn |
| Jun 30, 2021 | 62.02 Bn |